🧬 Newborn Screening for #Duchenne (DMD) is here❗ DMD & MLD were added to the US RUSP—unlocking earlier diagnosis, earlier treatment, and stronger family support 🍼💪 Read more: www.neurologylive.com/view/newborn... #RareDisease #Neurology #NewbornScreening #Neuromuscular #PublicHealth #GeneticTesting

🧬 Promising DMD data from #REGENXBIO: RGX-202 patients beat expected disease progression on NSAA at 12 & 18 months. 🚀 BLA planned for 2026 as trials expand globally. Read more: www.neurologylive.com/view/patient... #DMD #GeneTherapy #ClinicalTrials #RareDisease #Neurology #BrainHealth

🧬 #FDA approves Zycubo—the FIRST treatment for pediatric Menkes disease! 💉 Subcutaneous copper histidinate boosts survival, especially when started in the first 4 weeks of life. What could newborn screening change? 👶✨ Read more: www.neurologylive.com/view/fda-app... #MenkesDisease #FDAApproval

🧠✨ Promising news in Dravet syndrome: Phase 3 EMPEROR results for zorevunersen are now expected by mid-2027, with an FDA NDA planned soon after. A potential step toward disease modification. Read more: www.neurologylive.com/view/phase-3... #Dravet #EpilepsyResearch #RareDisease #Biotech #Neurology

Big news in neurology❗ Annexon has submitted an EMA marketing application for tanruprubart, a first-in-class C1q antibody for Guillain-Barré syndrome. #Phase3 data show faster, more complete recovery & QoL gains. Read more below 👇 www.neurologylive.com/view/annexon... #GBS #Neurology #Biotech

🧠⚡ BMB-101 advances toward registrational trials after positive phase 2 data in drug-resistant absence seizures & developmental epileptic encephalopathies. Read more on what’s next: www.neurologylive.com/view/bmb-101... #Epilepsy #ClinicalTrials #NeuroPharma #RareDisease #DrugDevelopment #Seizures

🧠💊 New #epilepsy research: Fenfluramine improved everyday executive functioning in adults with Lennox-Gastaut syndrome—independent of seizure reduction. Read more 👉 www.neurologylive.com/view/fenflur... #LGS #Neurology #AES2025 #MedicalNews #BrainHealth

🧠🩺 Early treatment can change lives—but inequities still delay care for infants with epileptic spasms. At #AES2025, Drs. Christina Briscoe & Emily Spelbrink unpacked system-level barriers and paths toward equity Read more 👇 www.neurologylive.com/view/neurovo... #Epilepsy #Neurology #PedsNeuro

🧠📊 #FDA Action Update: December 2025 From a low-sodium oxybate NDA acceptance to a new approval in gMG —and key trial updates in ALS & MS—the FDA closed out 2025 with major neurology decisions shaping the pipeline Read more 👉 www.neurologylive.com/view/fda-act... #Neurology #ClinicalTrials #Approve

🧠 New 2025 #NMOSD diagnostic guidelines are here! Experts clarify AQP4+ vs antibody-negative disease, spotlight mimics like MOGAD, and aim to protect access to FDA-approved therapies 💊 Read more → www.neurologylive.com/view/clinica... #Neurology #RareDisease #ClinicalGuidelines

🧠 NeurologyLive® Year in Review 2025 highlights key #Alzheimer disease trials that could reshape care—spanning anti-amyloid, anti-tau, immunotherapy, and prevention-focused studies From DIAN-TU to AHEAD 3-45, here’s what to watch 👇 www.neurologylive.com/view/neurolo... #Neuro #ADResearch #AD

At #AES2025, Joseph Sullivan, MD reviewed early POLARIS phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy targeting SCN1A in inhibitory interneurons—showing encouraging #seizureReduction & developmental gains in young children. 👉 Read more: www.neurologylive.com/view/neurovo...

🧠🎮 Test your neurology knowledge! This week’s NeurologyLive® Brain Games dives into neuromodulation for Parkinson disease—covering DBS targets, adaptive systems & more. Take the 3-question quiz and share your score! Read more 👉 www.neurologylive.com/view/neurolo... #Neurology #PD #Braingames

🧠 Breakthrough in #Parkinson research 🔬 GT-02287 reduced CSF GluSph, signaling improved GCase activity, with favorable safety in Phase 1b trials. A key biomarker milestone for #PD therapies. Read more 👉 www.neurologylive.com/view/brain-p... #Biotech #ClinicalTrials #Neurology #Neuroscience

🚨 New Podcast Launch 🚨 Frontlines with Frontera makes its debut today! Hosted by Jennifer Frontera, MD, the series brings thoughtful, clinician-to-clinician conversations on the toughest questions in acute #neurology and #neurocritical care. Episode 1 is live! www.neurologylive.com/view/frontli...

🧬 Genetic #Epilepsy in Adults Network (GEAN) aims to standardize genetic testing in adults and define adult outcomes for rare genetic epilepsies. GEAN is a new AES-funded consortium and Elizabeth Gerard, MD explains why it matters. 🔗 ➡️ www.neurologylive.com/view/genetic... #AES2025 #Genetic #Gene

🧠⚡ Long-term data on azetukalner (XEN1101), a first-in-class Kv7 channel opener, show sustained #seizure reduction and meaningful seizure-freedom signals in focal onset seizures. What could this mean for care? Read more 👉 www.neurologylive.com/view/underst... #Epilepsy #AES2025 #Neurology

Post–cardiac arrest seizures demand precision, not just more monitoring. At #AES2025, Andrea Rossetti, MD highlights why routine #EEG can rival continuous EEG, how prognostication guides treatment, and where broader-spectrum ASMs may fit best. Read more: www.neurologylive.com/view/refinin...

🎧 New Mind Moments episode! Sneha Mantri, MD, MS joins the podcast to break down how mood, anxiety, and behavior shape life with Parkinson disease—often long before motor symptoms appear. Listen here ➡️ www.neurologylive.com/view/episode... #PD #Neurology #MovementDisorders #MindMoments #NeuroCare

🚨 Major #DMD breakthrough: Deramiocel hits its #Phase3 endpoint! 💪 54% slower loss of upper-limb function ❤️ 91% slower decline in cardiac function A huge moment for Duchenne research and regulatory momentum. Read here: www.neurologylive.com/view/cell-th... #RareDisease #Biotech #Neurology

At #AES2025, interim POLARIS Phase 1/2 data showed ETX101 achieved: 🔹 78% median seizure reduction at DL3 🔹 Significant gains in communication & cognitive development 🔹 Favorable safety with no treatment-related serious AEs 🔗 ➡️ www.neurologylive.com/view/gene-th... #Neurology #Epilepsy #AE #Health

🆕 #Phase3 data from the #EVOKE trials show semaglutide did not slow progression of early #AD 🔹 No significant benefit on CDR-SB, ADCS-ADL-MCI, or cognitive composites 🔹 #Biomarkers: reductions in pTau181/217 and hs-CRP, but no clinical impact 🔹 Read more: www.neurologylive.com/view/ctad-pr...

New data presented at #CTAD2025 📊 Etalanetug cut tau pathology biomarkers fast in dominantly inherited #Alzheimer Key Changes: 🧬 CSF eMTBR-tau243 ↓ 62% 🩸 Plasma eMTBR-tau243 ↓ 78% Read more here: www.neurologylive.com/view/ctad-po... #AD #Neurology #TAU #BrainHealth #Conference #Coverage #Neuro

🌅 Early #Phase3 data on remternetug shows that subcutaneous self-administration is feasible for early #Alzheimer patients ~30% of participants self-injected at least once, with higher uptake among ApoEε4 carriers and those with higher MMSE scores 🔗 ➡️ www.neurologylive.com/view/early-p... #Neuro

🆕 real-world #data 📊 Galcanezumab cuts monthly #migraine & #headache days by 50%+ in most patients — with generally mild side effects Galcanezumab is the only #CGRP monoclonal antibody with high response rates in episodic migraine headache populations 🔗 ➡️ www.neurologylive.com/view/real-wo...

New #NeuroVoices interview 🚨 Dr. Christina Briscoe highlights why rapid #diagnosis and early #treatment are critical for infantile epileptic spasms—and why care still varies widely. More work is needed on pathways, access, and equity Read More: www.neurologylive.com/view/neurovo... #Epilepsy

📣 New FDA Approval The #FDA has approved the intrathecal form of #SMA gene therapy Itvisma for patients 2+. STEER showed meaningful motor gains and #STRENGTH confirmed safety in those switching from Spinraza/Evrysdi. 💙🧬 Read more here: www.neurologylive.com/view/fda-app... #Approval #Neurology

🧠 This Week on NeurologyLive® From cutting-edge clinical insights to expert-led analyses, #NeurologyLive is diving into the hottest topics in #neurology this week. Explore what’s coming and stay ahead in the field of #neurological care: www.neurologylive.com/view/this-we... #NeuroTwitter #Preview

🧠 New insights in #CIDP care: Dr. Amit Sachdev highlights how personalized treatment—IVIg, SCIG, and emerging targeted therapies—can help patients move beyond the “maintenance plateau.” More flexibility, better long-term outcomes ✨ Read More: www.neurologylive.com/view/optimiz... #Neurology

“Every stroke is different… and so is every recovery.” At #AAPMR2025, Dr. Talya Fleming talked about why access to stroke rehab still isn’t equal—and how new tech and home-based care could help. Great Insights on what it takes to rebuild life after #stroke: www.neurologylive.com/view/underst...

🚨 New hope in Parkinson research! At #MDS2025, Dr. Tanya Simuni highlighted major breakthroughs in disease-modifying therapy trials for Parkinson disease. 🧠✨ Read more: www.neurologylive.com/view/neurovo... #Parkinson #Neurology #ClinicalTrials #NeuroScience #PD

New study in Headache shows Nerivio® REN wearable delivers 3 years of stable migraine relief with no tachyphylaxis 🎉 Drug-free, app-controlled, and effective for both youth & adults. ⏱️ Early use = up to 2× better outcomes! 👉 Read more & join the discussion: www.neurologylive.com/view/nerivio...

🧠 New week, new insights on NeurologyLive®! We’re covering the biggest conversations in #neurology —clinical updates, expert perspectives, and more. Don't miss out! Take a look & dive into the full lineup here: www.neurologylive.com/view/this-we... #BrainHealth #Updates #Interviews #News #Coverage

🚨 New Podcast Ep.! NEALS 2025: Takeaways That Matter for ALS Care - Featuring Dr. Berry and Dr. Andrews! Listen as they reflect on key themes from the 2025 NEALS Annual Meeting, now reintroduced as the Network of Excellence for #ALS. 👂 ➡️ www.neurologylive.com/view/episode... #MindMoments #Podcast

Breakthrough for #Parkinson patients: iPSC therapy UX-DA001 boosts motor function & dopamine activity—without serious side effects. Learn how #CellTherapy may transform brain repair. 🧠 Read the full story 👉 www.neurologylive.com/view/therape... #StemCellTherapy #NeuroResearch #Neurology #Health

🌍 A new dawn for #RareDisease care: #FDA approves Kygevvi, the first treatment for thymidine kinase 2 deficiency (TK2d). 💡 Data show an 86% reduction in mortality risk — a life-changing advance for patients & families. Read here: www.neurologylive.com/view/neurovo... #Neurology #Innovation

Caregivers are open to talking about social determinants of health (SDoH) — but prefer surveys over face-to-face discussions. A new study finds many want to focus clinic time on their child’s care while still sharing key life factors that affect health. 🔗 ➡️ www.neurologylive.com/view/study-s...

🧠 This Week on #NeurologyLive From conference coverage to video interviews to up to the minute news — we’re diving into the latest research, expert insights, and clinical updates shaping the field of #neurology. Don’t miss this week’s coverage 👉 www.neurologylive.com #BrainHealth #NeurologyUpdates

⚡ EVs may reduce emissions — but could they raise neurologic risks globally? Dr. Brad Racette (Barrow Neurological Institute) explores how EV production shifts environmental & neurotoxic burdens to the global south. Read more 👉 www.neurologylive.com/view/overvie... #EVs #Risks #Neurology #Health

💡 Promising results for #ALS patients! Phase 2a data show SPG302 (Spinogenix’s synaptic regenerative drug) slowed ALS progression by 76% vs historical controls, with 82% of patients showing stable or improved function. Read more: www.neurologylive.com/view/prelimi... #Neuroscience #Neurology

In case you missed it: 🚨 Breaking: FDA Approves First Treatment for TK2 Deficiency The #FDA has approved Kygevvi — a fixed-dose combo of doxecitine + doxribtine — as the first-ever therapy for thymidine kinase 2 deficiency. Stay up to date here: www.neurologylive.com/view/fda-app... #Neurology

A new #Phase3 trial, RELIEVE, is underway to evaluate remibrutinib, a potent oral BTK inhibitor, in #gMG. 💊 Builds on strong safety data from autoimmune studies and FDA approval in CSU. 🧬 Could mark a new era in targeted gMG treatment. Read here: www.neurologylive.com/view/new-pha... #Neurology

🧠 This Week on NeurologyLive® — Nov 3, 2025 From #Alzheimer’s and #epilepsy to sleep and stroke, we’re diving into the week’s hottest topics in neurology. Explore expert insights, in-depth analyses, and clinical updates designed for professionals in the field. 🔗 neurologylive.com #Neurology #Care

The results from our #AI in #MultipleSclerosis survey are in. Take a look over on @neurologylive.bsky.social. www.neurologylive.com/view/ai-in-m...

🎃 This Halloween, neurology meets history 📜 Avi Singh Gandh, MD, explores how the “bewitchments” of the 1692 Salem Witch Trials may reflect epilepsy, FND, and more —reminding us how science turns fear into understanding. Read more: www.neurologylive.com/view/revisit... #Halloween #AAN25 #Spooky

This #WorldStrokeDay, Cleveland Clinic’s Dr. Andrew Russman highlights how most strokes stem from identifiable and modifiable risks — and how precision medicine and heart–brain collaboration are reshaping prevention. Read more via NeurologyLive®: www.neurologylive.com/view/honorin...

❤️ “Maintaining healthy numbers for Life’s Essential 8 can reduce the risk of #stroke and #dementia.” — Dr. Mitch Elkind Ahead of #WorldStrokeDay, NeurologyLive® spoke with Dr. Elkind on prevention, equity, and the future of brain health. Read more: www.neurologylive.com/view/neurovo... #Health

🚨 FDA Accepts NDA for MK-6240 — a PET imaging agent targeting tau protein in #Alzheimer disease. 🔬 Developed by Lantheus, MK-6240 aims to improve early diagnosis and guide treatment strategies for patients with cognitive impairment. 📖 Read more: www.neurologylive.com/view/fda-acc... #FDA #News

This Week’s Preview 🫣 Stay ahead in neurology with our latest coverage! Coming up: exclusive clinician interviews, continued conference insights, a new podcast episode, and more. 🕐 Take 5 minutes to stay informed → www.neurologylive.com/view/this-we... #Neurology #Research

"Lifestyle factors are not secondary—they’re central" New insights from Dr. James N. Brenton at the 2025 Child Neurology Society Annual Meeting on how #diet, vitamin D, and obesity impact pediatric MS progression—and why coordinated care matters. Full article: www.neurologylive.com/view/integra...